Back to our patient…
Treatment: OBSERVATION (patient continues on MEK Inhibitor)
Follow-up 2 weeks later: nearly all fluid has resolved corresponding to improvement in vision
BCVA: 20/20
BCVA: 20/20
Sponsored by:
Sponsored by:
Back to our patient…
Treatment: OBSERVATION (patient continues on MEK Inhibitor)
Follow-up 2 weeks later: nearly all fluid has resolved corresponding to improvement in vision
BCVA: 20/20
BCVA: 20/20